In MASLD, while data on the total hepatic CD4+ T cell numbers are conflicting [96], there is evidence of a Th1/Th17 shift and increased IFNγ and IL-17A levels, promoting inflammation and fibrosis [96,97,98]. The gene discussed is CD4; the disease is metabolic dysfunction-associated steatotic liver disease.